Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Zenocutuzumab

Catalog #:   DHC09609 Specific References (32) DATASHEET
Host species: Humanized
Isotype: IgG1-kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHC09609

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

p185erbB2, HER2, NGL, Tyrosine kinase-type cell surface receptor HER2, NEU, MLN 19, Proto-oncogene Neu, MLN19, ERBB2, Proto-oncogene c-ErbB-2, CD340, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, ERBB3, HER3, Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, Receptor tyrosine-protein kinase erbB-3

Concentration

1.75 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P04626 & P21860

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Bispecific, MCLA-128, PB4188, R040517, CAS: 1969309-56-5

Clone ID

Zenocutuzumab

Data Image
  • SDS-PAGE
    SDS PAGE for Zenocutuzumab
  • Bioactivity
    Detects CD340/ERBB2/HER2/NEU in indirect ELISAs.
References

Zenocutuzumab Shines in PDAC, PMID: 34112697

Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade, PMID: 29763625

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose, PMID: 29728897

NRG1 fusions: Biology to therapy, PMID: 34098222

The Exciting New Field of HER2-Low Breast Cancer Treatment, PMID: 33804398

A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G 1, PMID: 28655766

Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration., PMID:40397846

eNRGy: Making progress toward a future for NRG1 fusion-positive cancer., PMID:40220746

Emerging importance of HER3 in tumorigenesis and cancer therapy., PMID:40087402

Zenocutuzumab: First Approval., PMID:39994106

Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours., PMID:39979643

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review., PMID:39971274

Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer., PMID:39908431

NRG1 Fusions: The New Kid on the Block., PMID:39888568

The use of zenocutuzumab for NRG1 fusion-positive tumors., PMID:39820371

Zenocutuzumab (Bizengri) for NSCLC and pancreatic adenocarcinoma., PMID:39819990

Antibodies to watch in 2025., PMID:39711140

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions., PMID:38348690

Antibodies to watch in 2024., PMID:38178784

Profiling of gene fusion involving targetable genes in Chinese gastric cancer., PMID:36160735

An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)., PMID:36107417

Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion-Positive, Estrogen Receptor-Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor., PMID:35977350

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements., PMID:35135829

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines., PMID:35035535

[Not Available]., PMID:34969512

Zenocutuzumab Shines in PDAC., PMID:34112697

NRG1 fusions: Biology to therapy., PMID:34098222

The Exciting New Field of HER2-Low Breast Cancer Treatment., PMID:33804398

Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors., PMID:32006223

Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade., PMID:29763625

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose., PMID:29728897

A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1., PMID:28655766

Datasheet

Document Download

Research Grade Zenocutuzumab.pdf

 

$ 484
Product specifications
100 μg 484 1 mg 1932

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Zenocutuzumab [DHC09609]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only